Wolfram Zimmermann

Wolfram-Hubertus Zimmermann is Professor and Director of the Institute of Pharmacology and Toxicology at the University Medical Center Göttingen. His research interests include: (1) development and translation of stem cell-based tissue engineered therapeutics; (2) therapeutic genome editing; (3) human organoids for disease modelling and drug discovery; (4) inter-cellular and inter-organ cross-talk in organ damage and repair. Major organs/tissue of interest include heart muscle, skeletal muscle, nervous system, and connective tissue. Zimmermann is the initiator of the first-in-human BioVAT-HF-DZHK20 trial, which is testing tissue engineered heart repair with Engineered Human Myocardium (EHM) from induced pluripotent stem cells in patients with advanced heart failure. His track record includes >200 publications, 13 patents, and the founding of several spin-offs (e.g., Repairon, myriamed, MyriaMeat).